Compare KMT & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMT | LQDA |
|---|---|---|
| Founded | 1938 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.5B |
| IPO Year | N/A | 2018 |
| Metric | KMT | LQDA |
|---|---|---|
| Price | $29.20 | $34.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $25.83 | ★ $37.40 |
| AVG Volume (30 Days) | 809.0K | ★ 1.7M |
| Earning Date | 02-04-2026 | 11-03-2025 |
| Dividend Yield | ★ 2.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.22 | N/A |
| Revenue | ★ $1,982,871,000.00 | $69,216,000.00 |
| Revenue This Year | $7.69 | $904.79 |
| Revenue Next Year | $3.82 | $188.25 |
| P/E Ratio | $24.03 | ★ N/A |
| Revenue Growth | N/A | ★ 343.41 |
| 52 Week Low | $17.30 | $10.37 |
| 52 Week High | $29.89 | $35.54 |
| Indicator | KMT | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 70.35 | 64.53 |
| Support Level | $27.47 | $32.11 |
| Resistance Level | $29.89 | $35.54 |
| Average True Range (ATR) | 0.58 | 1.55 |
| MACD | 0.04 | -0.10 |
| Stochastic Oscillator | 74.80 | 76.90 |
Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.